Funding: GSK (212620) Disclosures: Gideon Hirschfield: Intercept: Consultant, GSK: Consultant, CymaBay: Consultant, Ipsen: Consultant, Falk: Consultant, Pliant: Consultant, Morphogen: Consultant, Roche: Consultant, Mirum: Consultant, Advanz: Consultant, Chemomab: Consultant, Gilead: Consultant, Kowa: Consultant, Christopher Bowlus: Calliditas: Grant/Research Support, ChemoMab: Grant/Research Support, ChemoMab: Consultant, COUR Phamaceuticals: Grant/Research Support, Cymabay: Grant/Research Support, Cymabay: Consultant, Cymabay: Consultant, Gilead: Grant/Research Support, GSK Pharmaceuticals: Grant/Research Support, GSK Pharmaceuticals: Consultant, Hanmi: Grant/Research Support, Intercept: Grant/Research Support, Invea Therapeutics: Consultant, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, NGM Bio: Consultant, Novartis: Grant/Research Support, Novo Nordisk: Grant/Research Support, Pliant Therapeutics: Grant/Research Support, Pliant Therapeutics: Consultant, Viking Therapeutics: Grant/Research Support, Zydus Therapeutics: Grant/Research Support, David Jones: Nothing to Disclose, Andreas Kremer: Abbvie: Advisor, Advanz: Advisor, Alentis: Advisor, AlphaSigma: Speaking and Teaching, AstraZeneca: Advisor, Avior: Advisor, Bayer: Advisor, CymaBay: Advisor, Escient: Advisor, Falk: Speaker, Falk: Speaker, Gilead: Advisor, GSK: Advisor, Intercept: Advisor, Ipsen: Speaking and Teaching, Ipsen: Speaking and Teaching, Mirum: Advisor, Mirum: Advisor, MSD: Advisor, Myr: Advisor, Roche: Advisor, Takeda: Advisor, Viofor: Advisor, Marlyn Mayo: CymaBay: Grant/Research Support, CymaBay: Consultant, GSK: Grant/Research Support, GSK: Consultant, Intercept: Grant/Research Support, IntraSana: Consultant, Ipsen: Grant/Research Support, Ipsen: Consultant, Mallinckrodt: Grant/Research Support, Mallinckrodt: Consultant, Mirum: Grant/Research Support, Target RWE: Grant/Research Support, Atsushi Tanaka: Nothing to Disclose, Pietro Andreone: Nothing to Disclose, Jidong Jia: Nothing to Disclose, Qinglong Jin: Nothing to Disclose, Ricardo Macas-Rodrguez: Nothing to Disclose, Alexander Cobitz: Nothing to Disclose, Brooke Currie: GSK: Employee, GSK: Stock - publicly traded company, Ciara Gorey: Nothing to Disclose, Eunhye Kang: Nothing to Disclose, Ivana Lazic: GSK: Employee, Danielle Podmore: Nothing to Disclose, Andrea Ribeiro: Nothing to Disclose, Jennifer Shannon: Nothing to Disclose, Brandon Swift: GSK: Employee, Philip Troke: Nothing to Disclose, Megan McLaughlin: Nothing to Disclose, Cynthia Levy: Cymabay: Grant/Research Support, Cymabay: Consultant, Intercept: Grant/Research Support, Intercept: Consultant, Calliditas: Grant/Research Support, Calliditas: Consultant, GSK: Consultant, GSK: Grant/Research Support, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, Mirum: Consultant, Zydus: Grant/Research Support, Gilead: Grant/Research Support, Gilead: Consultant, Escient: Grant/Research Support, Kowa: Grant/Research Support, Kowa: Consultant, Genfit: Grant/Research Support, COur: Advisor, Chemomab: Consultant 2362 PERIDUCTAL IRON-CORRECTED T 1 IS A PREDICTOR OF ADVERSE OUTCOMES IN LARGE-DUCT PRIMARY SCLEROSING CHOLANGITIS Emmanuel Selvaraj 1 Bruno Paun 2 Cayden Beyer 2 Amy Herlihy 2 Michael Brady 2 Emma Culver 1 Adam Bailey 1 Michael Pavlides 3 , 1 University of Oxford, 2 Perspectum Ltd, 3 Oxford University Background: Concentric periductal fibrosis, commonly referred to as onion skin fibrosis, is a histological hallmark of primary sclerosing cholangitis (PSC)
Glutathione is one of the most essential antioxidants produced in our body and is responsible for helping to detoxify alcohol from our system
Glutathione's primary function in our bodies is to combat oxidative stress, which can damage cells and lead to various diseases, including cancer
Serious allergic reactions: Stop using Ozempic and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat
We used 70% of the cohort to train and 30% to test the machine learning models
2023 Sep 6
